2543

Weekly cabazitaxel in "unfit" metastatic castration resistant prostate cancer patients (mCRPC) progressing after docetaxel (D) treatment. CABASEM-SOGUG phase II trial

E.M. Fernandez Parra1, M. Ochoa2, D. Castellano15, L. Munie10, M.J. Juan1, B. Perez Valderrama2, B. Mellado6, O. Fernandez Calvo10, U. Anido10, M. Dormenech2, S. Hernandez12, J.A. Arranz1, C. Caballero10, M. Campayo2, P. Esteve2, L. Leon15, M.A. Climent14, Hospital de Valme, Servicio de Oncologia Medica, Sevilla, Spain; 2Hospital Duran i Reynals, Servicio de Oncologia Medica, Barcelona, Spain; 3Complejo Hospitalario Universitario de Santiago, Laboratorio de Oncologia Translacional, Santiago de Compostela, Spain; 4Fundación Instituto Valenciano de Oncologia, Oncologia Medica, Valencia, Spain; 5Hospital Universitario Virgen del Rocio, Servicio de Oncologia Medica, Sevilla, Spain; 6Hospital Clinic, Servicio de Oncologia Medica, Barcelona, Spain; 7Complejo Hospitalario Universitario de Ourense, Servicio de Oncologia Medica, Ourense, Spain; 8Hospital Clinico Universitario de Santiago, Servicio de Oncologia Medica, Santiago de Compostela, Spain; 9Hospital Althaea de Manresa, Servicio de Oncologia Medica, Barcelona, Spain; 10Hospital Universitario Fundación Alcorcón, Servicio de Oncologia Medica, Alcorcon, Spain; 11Hospital Universitario General San Juan de Alicante, Servicio de Oncologia Medica, Alicante, Spain; 12Hospital General Universitario de Valencia, Servicio de Oncologia Medica, Valencia, Spain; 13Complejo Hospitalario Universitario de Pontevedra, Servicio de Oncologia Medica, Pontevedra, Spain; 14Fundación Instituto Valenciano de Oncologia, Oncologia Medica, Valencia, Spain; 15Hospital 12 de Octubre, Madrid, Spain

Background: Cabazitaxel (C), a novel taxane developed to overcome D resistance, showed an overall survival improvement after D in mCRPC in a three-weekly schedule. Its main toxicity is hematological, especially in unfit patients (Pts). We aimed to evaluate efficacy and safety of weekly Cipredinione (P) schedule in “unfit” mCRPC previously treated with D. Possible relation of CTC counts and its early response with efficacy is analyzed.

Methods: Pts with mCRPC progressing after D treatment with adequate bone marrow, liver and kidney functions were included in this open-label non-comparative trial. Unfit pts defined as ECOG >2, no reduction due to febrile neutropenia during D treatment or radiation therapy affecting more than 25% of bone marrow reserve. C 10 mg/m² was administered on days 1, 8, 15 and 22 of 5-week cycles with P (5 mg b.i.d.).. Radiological and PS were evaluated according to the PCWG2 criteria and toxicity according NCI-CTC AE.

Results: 70 pts have been enrolled and 1 of them is still on treatment. Median age was 73 yr (range 54–85). 71% pts had ECOG 2, 81% had bone, 16% liver and 11% lung metastases. Treatment: 3/2 cycles (median: 3; range: 1–14); 116 weekly infusions (median: 11; range: 1–54). Median dose intensity was 89%. Twenty-two of 59 pts (37.3%) showed an overall survival improvement after D in mCRPC in real-world. The primary objective of this study was to evaluate treatment duration associated with AA treatment in routine clinical practice in mCRPC patients in the post-chemotherapy setting across four European countries: Belgium, France, Germany and the Netherlands. Other clinical data such as treatment sequencing and survival were assessed to place the treatment duration into context.

Material and Methods: The study was designed as a retrospective chart review. Patients were identified through treating oncologists and urologists registered in the IMS Health Medical Radiologist physician database. Eligible mCRPC patients were aged ≥18 years at AA initiation (i.e. baseline), previously treated with docetaxel and naïve to prior AA treatment. Baseline patient characteristics were described using summary statistics. Kaplan–

2544

Abiraterone acetate in metastatic castration-resistant prostate cancer after chemotherapy. A retrospective “Real Life” analysis of activity and safety

M.A. Fabbri1, E. Cortesi2, P. Marchetti1, D. Santini1, T. Gamucci5, F. Angelini3, F. Longo10, A. Milano10, M.L. Mancini10, A. Giuli2, S. Quadrini2, I. Sperduti3, A. Pellegrino3, R. Ratt1, F. Primi5, M.G. Chellet1, E.M. Ruggieri1, Ospedale Belluno, UOC Oncology, Vittorio, Italy; 2Policlinico Umberto I, UOC Oncology B, Rome, Italy; 3Ospedale Sant’Andrea, UOC Oncology, Rome, Italy; 4Campus Biomedico, UOC Oncology, Rome, Italy; 5Ospedale SS Trinità, UOC Oncology, Sora, Italy; 6Regina Apostolorum, UOC Oncology, Albano Laziale, Italy; 7Policlinico Umberto I, UOC Oncology A, Rome, Italy; 8Istituto Regina Elena, Biostatistics Unit, Rome, Italy; 9San Pietro FBF, UOC Oncology, Rome, Italy

Background: Abiraterone acetate (AA) is a potent, selective androgen (CYP17) biosynthesis inhibitor, which showed to improve overall survival (HR= 0.646) in mCRPC patients progressing after docetaxel. In this retrospective analysis we assessed the safety and efficacy of AA in patients affected with mCRCP progressing after chemotherapy, treated in the normal clinical practice, in several Italian Oncologic Units, after the approval of the drug from the Italian Drug Agency (AIFA)

Material and Methods: We retrospectively reviewed the clinical data of patients affected with mCRC progressive after chemotherapy who received AA (1000 mg/d) plus prednisone (5mg/twice daily). Pts were considered eligible if they had received docetaxel as prior chemotherapy. A total of 189 patients were included in the analysis. Main patient characteristics were median age: 70 years (range 44–89), Gleason score >7: 84%; median PSA at AA start: 35 (range 0.36–2100); duration of prior hormonal therapy <12 vs ≥12 months: 38 vs 62%; no. of metastatic sites: 1 vs ≥2: 73 vs 27%; bone only 48%; presence of visceral disease 51%; symptomatic vs non-symptomatic: 53 vs 47%; median number of prior docetaxel courses: 6 (range 1–15); second-line cabazitaxel: 14%. Forty-four percent of patients received bispophonates during AA treatment. AA: was well tolerated and no relevant toxicity was observed. After a median follow-up of 8.5 months (range 1–51) the median progression-free survival (PFS) and the median overall survival (OS) were 10 months (95% CI: 7–13) and 26 months (95% CI: 17–35) respectively. No differences in PFS and OS were found based on the response to docetaxel. Patients who received hormonal treatment for >12 months had a statistically significant longer PFS (13 vs 7 months, p = 0.009) and OS (28 vs 17 months, p = 0.033). The median decrease in the PSA level >50% was observed in 36% of patients. Patients with only bone metastasis had a PFS of 13 (95% CI: 7–18) and OS 28 months (95% CI:18–40). Twelve patients (6%) presented a scheletal-related event (SRE).

Conclusions: The results achieved in this analysis although retrospective, confirms the activity and safety of AA in these subset of patients.

No conflict of interest.

2545

Real-world treatment with abiraterone acetate in metastatic castration-resistant prostate cancer (mCRPC) patients in the post-chemotherapy setting in Europe

L. Dearden1, P. Musingingrim2, N. Shalet1, D. Demuth2, L. Garcia Alvarez2, A. Muthatlumiti1, A. Venerus2, R. Laisery, M. Hankins3, T. Mahen4, J. Janssen, EMEA HEMAR, High Wycombe, United Kingdom; 2IMS Health, Real World Evidence Solutions, London, United Kingdom; 3Janssen, Medical Affairs, High Wycombe, United Kingdom

Background: In the COU-193 trial, abiraterone acetate plus low dose prednisone (AA) was found to extend survival in metastatic castrate resistant prostate cancer (mCRPC) patients progressing after docetaxel chemotherapy compared to placebo plus low dose prednisone. However, limited data related to AA treatment and outcomes is available in the real-world. The primary objective of this study was to evaluate treatment duration associated with AA treatment in routine clinical practice in mCRPC patients in the post-chemotherapy setting across four European countries: Belgium, France, Germany and the Netherlands. Other clinical data such as treatment sequencing and survival were assessed to place the treatment duration into context.

Material and Methods: The study was designed as a retrospective chart review. Patients were identified through treating oncologists and urologists registered in the IMS Health Medical Radiologist physician database. Eligible mCRPC patients were aged ≥18 years at AA initiation (i.e. baseline), previously treated with docetaxel and naïve to prior AA treatment. Baseline patient characteristics were described using summary statistics. Kaplan–